Company patents
Halozyme, Inc.
Halozyme, Inc. surprisingly shows a significant, albeit fluctuating, focus on "Peptides & Proteins" (48.0% of portfolio) and "Material & Chemical Analysis" (46.7%), both of which saw explosive growth in 2024 (YoY +2100.0% and +400.0% respectively) before sharp declines in 2025 and so far in 2026, suggesting a dynamic but potentially volatile R&D pipeline beyond its core "Pharmaceutical Preparations" (85.3% of portfolio) which also saw a 38.5% decline in 2025.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
75 US filings (since 2023) · 6 categories · 8 themes
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Mechanical or electromechanical systems designed for precise, often self-administered, delivery of medicaments, including features for dose setting, needle insertion/retraction, and safety mechanisms to prevent premature activation.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.
Patents
Showing 1-2 of 2
Protein & Peptide Engineering